Leerink Partnrs Boosts Earnings Estimates for Kura Oncology

Kura Oncology, Inc. (NASDAQ:KURA) – Research analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Kura Oncology in a report released on Thursday, November 21st. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings per share of ($2.19) for the year, up from their previous estimate of ($2.51). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Leerink Partnrs also issued estimates for Kura Oncology’s Q4 2024 earnings at ($0.39) EPS and FY2025 earnings at $0.70 EPS.

Several other brokerages also recently issued reports on KURA. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Thursday. HC Wainwright raised their target price on shares of Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and reduced their target price for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. TD Cowen reiterated a “buy” rating on shares of Kura Oncology in a research note on Thursday. Finally, Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.38.

Kura Oncology Trading Up 7.4 %

Shares of NASDAQ KURA opened at $10.80 on Monday. Kura Oncology has a fifty-two week low of $9.06 and a fifty-two week high of $24.17. The firm has a market capitalization of $839.81 million, a P/E ratio of -4.58 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The company’s 50 day simple moving average is $17.88 and its 200 day simple moving average is $19.67.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors have recently made changes to their positions in KURA. nVerses Capital LLC bought a new position in Kura Oncology during the 3rd quarter worth approximately $25,000. SG Americas Securities LLC bought a new stake in shares of Kura Oncology in the 1st quarter worth approximately $110,000. Point72 DIFC Ltd bought a new position in shares of Kura Oncology during the third quarter valued at $146,000. Quarry LP purchased a new position in shares of Kura Oncology in the 2nd quarter worth about $196,000. Finally, Erste Asset Management GmbH bought a new stake in Kura Oncology during the 3rd quarter valued at about $215,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.